Semaglutide Medicinal

Semaglutide for Weight Loss: What the Research Shows

What the STEP trials established

Semaglutide for weight loss — specifically the 2.4 mg subcutaneous once-weekly formulation — has produced the largest mean weight reductions of any single-agonist GLP-1 agent in Phase 3 trials. The STEP trial program enrolled thousands of adults across multiple populations and followed participants for up to 2 years, establishing a consistent quantitative picture of weight loss magnitude, timeline, and durability.

Semaglutide's weight loss mechanism combines two central effects: hypothalamic GLP-1 receptor activation suppressing energy intake, and gastric motility delay extending postprandial satiety [12]. A 2023 rodent study additionally found dose-dependent suppression of food-reward motivation via VTA dopamine pathways — a mechanism that may partly explain the appetite reduction seen even at doses below the maintenance threshold [13].

STEP trial outcomes: the numbers

STEP-1 (n=1,961 adults with BMI ≥30 or ≥27 with comorbidities; 68 weeks): 14.9% mean body weight reduction with semaglutide 2.4 mg versus 2.4% with placebo (treatment difference 12.5 percentage points). 86.4% of semaglutide participants achieved ≥5% weight loss versus 31.5% with placebo; 69.1% achieved ≥10%; 50.5% achieved ≥15%; 31.5% achieved ≥20% [1]. These are not outliers — they are the central tendency of a 1,961-person trial.

STEP-5 (n=304; 104 weeks): at 2 years, mean weight reduction was 15.2% with semaglutide versus 2.6% with placebo — treatment difference 12.6 percentage points. 77.1% of semaglutide participants maintained ≥5% weight loss at 2 years versus 34.4% with placebo [6]. No clinically meaningful plateau was observed; weight reduction was maintained through week 104.

STEP-2 (n=1,210 adults with type 2 diabetes and BMI ≥27): 9.6% mean weight reduction versus 3.4% with placebo [14]. The lower magnitude than STEP-1 is consistent across GLP-1 agonist trials in populations with T2D.

In SURMOUNT-5 — the head-to-head Phase 3b trial comparing semaglutide to tirzepatide — the semaglutide arm (max dose 2.4 mg) achieved a mean 13.7% weight reduction at week 72, which tirzepatide's mean was 20.2% [20]. Both outcomes substantially exceed prior pharmacological benchmarks for weight management.

Body Composition Changes in Semaglutide Trials

The DXA body composition substudy from STEP-1 (n=140) provides the clearest data on what the weight loss was composed of. At week 68:

  • Total fat mass: −19.3%
  • Visceral fat mass: −27.4%
  • Lean body mass: −9.7% (absolute), but +3.0 percentage points proportionally
  • Lean-to-fat ratio improved, particularly in the ≥15% weight loss subgroup [16]

The proportional preservation of lean mass — approximately 61% of weight lost was fat, versus 39% lean — is comparable to other hypocaloric interventions and does not represent a unique or disproportionate loss of muscle tissue [16]. The visceral fat reduction of 27.4% is notable: visceral adipose tissue is the metabolically active depot most strongly associated with cardiometabolic risk.

Weight Regain After Discontinuation

The STEP-4 withdrawal trial (n=803) is the clearest evidence on what happens when semaglutide is stopped. After a 20-week run-in, participants were randomized to continue semaglutide 2.4 mg or switch to placebo for an additional 48 weeks. Those continuing semaglutide lost an additional mean 7.9% body weight; those switched to placebo gained 6.9% — a between-group difference of 14.8 percentage points (P<0.001) [15].

The STEP-1 extension study (n=327 followed to week 120) provides a longer-term picture. Participants who stopped semaglutide at week 68 regained a mean 11.6 percentage points over the following year — approximately two-thirds of their prior weight loss. Net weight loss from baseline was 5.6% at week 120 [21].

Taken together, STEP-4 and the STEP-1 extension establish that semaglutide's weight reduction is largely dependent on continued treatment — a finding that raises the ongoing clinical research question of treatment duration, which STEP-5 and other long-term trials continue to study.